TX-SPINALCYTE,-LLC
SpinalCyte, LLC, a clinical stage regenerative medicine company focused on regrowth of the spinal disc using Human Dermal Fibroblasts (HDFs), today announced a new comprehensive resource to raise awareness of the potential benefits of fibroblasts and provide a growing knowledge base for this promising regenerative medicine technology.
The company’s website, www.spinalcyte.com , now features company and independent research studies demonstrating the potential of this new cell source for disc repair and other disease pathways.
“Fibroblasts hold significant advantages over mesenchymal stem cells,” said Dr. Thomas Ichim, Chief Scientific Officer of SpinalCyte and author of an analysis comparing the two cell sources published in the Journal of Translational Medicine . “As we and other leading researchers continue to advance the science in this field, our website will be the best place to find the latest and most up-to-date information on the healing power of fibroblasts.”
SpinalCyte is the leader in the field of HDF therapy with 52 U.S. and international patents issued and 85+ patents pending focused on the clinical utility of fibroblasts.
“Fibroblasts are the regenerative cell source of the future,” said Pete O’Heeron, Chief Executive Officer of SpinalCyte. “The breadth of our intellectual property demonstrates the versatility of this technology and positions us as the unquestioned frontrunner in this emerging sector. We look forward to presenting new research from around the globe highlighting the promise of fibroblasts.”
About Degenerative Disc Disease
Degenerative disc disease (DDD) is a condition in which a patient’s spinal disc breaks down and can begin to collapse. It is estimated that 85% of people over the age of 50 have evidence of disc degeneration and over 1.3 million procedures a year are performed to treat the disease. The most common treatments for patients with DDD are either discectomy or spinal fusion. Discectomy is the partial or full removal of the degenerated disc to decompress and relieve the nervous system but can cause long term spinal pain. In a spinal fusion procedure, the entire disc is removed and the two adjacent vertebrae are fused together. It often increases strain on the adjacent discs and surrounding tissues leading to further degeneration.
About CybroCell
CybroCell is the first off-the-shelf allogenic human dermal fibroblast (HDF) product for the treatment of degenerative disc disease. SpinalCyte’s Phase 1/Phase 2 clinical trial for injected human dermal fibroblasts in the treatment of DDD demonstrated after 18 months, patients injected with CybroCell had sustained improvement in pain relief and increased back mobility.
About SpinalCyte
Based in Houston, Texas, SpinalCyte, LLC, is a regenerative medicine company developing an innovative solution for spinal disc replacement using human dermal fibroblasts. Currently, SpinalCyte holds 52 U.S. and international issued patents and has filed for an additional 85+ patents pending and issued across a variety of clinical pathways, including disc degeneration, cancer, diabetes, liver failure and heart failure. SpinalCyte represents the next generation of medical advancement in cell therapy. Visit www.spinalcyte.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190515005305/en/
Contact:
David Schull or Ned Berkowitz Russo Partners LLC 858-717-2310 646-942-5629 david.schull@russopartnersllc.com ned.berkowitz@russopartnersllc.com
Clinical Contact: info@spinalcyte.com
Link:
Social Media:
https://www.facebook.com/LibertyStarLBSR/#!/pages/Liberty-Star-Uranium-Metals-Corp/135810219778400?r
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Celltrion Pharm Signs Strategic Trilateral Agreement with Becton Dickinson and BD Korea to Accelerate Global PFS CMO Business17.9.2025 02:00:00 CEST | Press release
Strengthen the PFS CMO business through a long-term partnership with global syringe leader BDExpand the global customer network by leveraging the BD&CMO Partnership ProgramTriple production capacity of the Cheongju plant by 2030, up from the current annual output of 16 million syringes Celltrion Pharm (KOSDAQ: 068706), a South Korean biopharmaceutical firm, said on September 16 that it has inked a strategic trilateral agreement with a multinational syringe manufacturer, Becton Dickinson France S.A.S. (BD), and its Korean branch BD Korea. The signing ceremony took place at Celltrion Pharm’s research center in Songdo, Incheon, with its President Yoo Young-ho in attendance alongside key officials from BD and BD Korea. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250914960476/en/ From left: Jeffrey Chen, Vice President, BD (Becton Dickinson) Greater Asia; Yoo Young-ho, President, Celltrion Pharm; and Jason Hwang, Country Gener
Mirion Partners with IAEA to Enhance Radiation Safety on a Global Scale16.9.2025 23:19:00 CEST | Press release
Partnership Agreement to Strengthen Radiation Detection and Measurement Capabilities at the Terrestrial Environmental Radiochemistry (TERC) Laboratory, Safeguarding the Environment and Promoting Nuclear Safety Mirion (NYSE: MIR), a leading provider of advanced radiation safety solutions, has signed a partnership agreement and practical arrangements with the International Atomic Energy Agency (IAEA), the world’s central intergovernmental forum for scientific and technical cooperation in the nuclear field, to cooperate in the area of radiation detection and measurement. Through this collaboration, Mirion’s advanced instrumentation and profound understanding of ionizing radiation will combine with the IAEA’s expertise and influence to advance the safe and secure use of nuclear technology worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916693003/en/ Mirion Chairman of the Board and CEO Thomas Logan and IAEA Director
NIQ and Displayce Collaborate to Bring Sales Lift Measurement to Europe’s DOOH Advertising Market16.9.2025 18:00:00 CEST | Press release
NIQ, a leading consumer intelligence company, and Displayce, a pioneering specialist technology suite for Out-of-Home advertising, are collaborating to bring advanced measurement capabilities to the European DOOH market. By combining NIQ’s trusted consumer intelligence with data from Displayce’s media activation platform, advertisers can link DOOH campaigns to in-store sales performance — driving transparency and accountability across the DOOH ecosystem. NIQ has long been a trusted source of consumer purchase insights for manufacturers and retailers, capturing the buying behavior of millions of households across more than 90 countries. Now, NIQ is extending its expertise and insights into the media ecosystem, empowering advertisers and agencies with new data assets and measurement solutions to improve their understanding of consumers and drive better ROI. Through the collaboration, NIQ and Displayce are driving the DOOH ecosystem toward more addressable, transparent, and results-driven
Capcom’s Resident Evil Requiem, the Latest Title in the Series, Also Coming to Nintendo Switch 2 on February 27, 2026!16.9.2025 15:00:00 CEST | Press release
– Additionally, two other Resident Evil series titles to be released for the console on the same date in step with Capcom’s multi-platform strategy – Capcom Co., Ltd. (TOKYO:9697) today announced that Resident Evil Requiem, the latest title in the Resident Evil series scheduled for release on February 27, 2026, for PlayStation®5 system, Xbox Series X|S, and PC, will also be released for Nintendo Switch™ 2 at launch. In addition, Resident Evil 7 biohazard and Resident Evil Village, two other titles in the series, will also be released for Nintendo Switch 2 on the same date. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916064724/en/ Resident Evil Requiem Key Art Resident Evil Requiem is a survival horror game that serves as the ninth main installment in the series. The title is being developed using RE ENGINE, Capcom’s proprietary game engine, and leverages Capcom’s extensive development experience cultivated over numerou
Aker BP Leverages Cognite Atlas AI™ to Pioneer an AI-First Future in Exploration and Production16.9.2025 15:00:00 CEST | Press release
Human insight and autonomous agents work together to transform operations, enhance efficiency, improve safety, and unlock new value across the enterprise. Aker BP, one of Europe's largest independent oil companies, and Cognite, the global leader in industrial AI, deepen their strategic partnership through the expanded adoption of Cognite Atlas AI™,harnessing the power of AI agents to improve efficiency, reduce costs, and elevate productivity. This enhanced collaboration puts Aker BP at the forefront of leveraging agentic AI to drive significant value and transform its operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903134233/en/ Aker BP Leverages Cognite Atlas AI™ to Pioneer an AI-First Future in Exploration and Production Aker BP's "AI-first strategy" was developed to help lead the energy sector into a data-driven future by seamlessly integrating AI applications within industrial settings and business objectiv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom